Company intelligence / Profile preview

Microbiologica

Cambridge, Essex, United Kingdom

Ownership: Private
Employees: ~45
Development stage: Other

Overview

Microbiotica is a leading clinical-stage biotechnology company developing personalized microbiome-based therapeutics and biomarkers. Its platform utilizes a proprietary culture collection and reference genome database to identify specific bacterial consortia that correlate with clinical outcomes. The company currently has two lead programs in Phase 1b clinical trials: MB097 for the treatment of melanoma and MB310 for ulcerative colitis.

Therapeutic areas: OncologyGastroenterology
Modalities: Live biotherapeutic product therapyMicrobial therapy
Industry: Biotech

Partnerships

GenentechRocheMSD

Beyond the preview

Go deeper on Microbiologica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Microbiologica.

Explore the full profile